Literature DB >> 6290

Studies on the centrally mediated hypotensive activity of guanabenz.

T Baum, A T Shropshire.   

Abstract

Prior studies demonstrated that guanabenz reduces systemic blood pressure by inhibiting central sympathetic outflow as well as by adrenergic neuron blockade. Potential mechanisms responsible for the reduction of efferent sympathetic activity were examined in the present series. Guanabenz failed to modify carotid sinus nerve activity in a perfused sinus preparation. It reduced sympathetic outflow, heart rate and blood pressure in debuffered cats indicating that its actions are not mediated primarily by baroreceptor mechanisms. alpha-Adrenergic blockade greatly attenuated the response suggesting that the central sympathoinhibitory effect of guanabenz results from alpha-adrenergic receptor activation. Only a high dose of the compound attenuated the increase in sympathetic nerve activity produced by stimulation of the posterior hypothalamus. These experiments lead to the overall conclusion that guanabenz acts primarily at sites which regulate the basal level of sympathetic outflow.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6290     DOI: 10.1016/0014-2999(76)90005-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  A basis for migraine therapy- the autonomic theory reappraised.

Authors:  E S Johnson
Journal:  Postgrad Med J       Date:  1978-04       Impact factor: 2.401

2.  Pharmacological characterization of B-HT 933 (2-amino-6-ethyl-4,5,7,8,-tetrahydro-6H-oxazolo-[5,4-d]-azepindihydrochloride) as a hypotensive agent of the "clonidine-type".

Authors:  W Kobinger; L Pichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

3.  The cardiovascular effects of MPV 295 [4(5)-2-(2,6-dimethylphenyl)ethylimidazole], a new antihypertensive agent with alpha 2-adrenoceptor agonistic properties.

Authors:  H Ruskoaho; J M Savola; S Kaipiainen; J Puurunen; N Kärki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

4.  Cardiovascular effects of alpha-adrenergic drugs: differences between clonidine and guanabenz.

Authors:  J S Gutkind; M Kazanietz; M A Enero
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

5.  Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors.

Authors:  R G Evans; W P Anderson
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

6.  Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis.

Authors:  Imaan Benmerzouga; Lisa A Checkley; Michael T Ferdig; Gustavo Arrizabalaga; Ronald C Wek; William J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

Review 7.  Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

8.  Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling.

Authors:  Kuo-Hao Ho; Yi-Ting Lee; Peng-Hsu Chen; Chwen-Ming Shih; Chia-Hsiung Cheng; Ku-Chung Chen
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

Review 9.  Remyelination Therapy in Multiple Sclerosis.

Authors:  Danielle E Harlow; Justin M Honce; Augusto A Miravalle
Journal:  Front Neurol       Date:  2015-12-10       Impact factor: 4.003

10.  Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic.

Authors:  Sharon W Way; Joseph R Podojil; Benjamin L Clayton; Anita Zaremba; Tassie L Collins; Rejani B Kunjamma; Andrew P Robinson; Pedro Brugarolas; Robert H Miller; Stephen D Miller; Brian Popko
Journal:  Nat Commun       Date:  2015-03-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.